Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants

Research output: Contribution to journalArticleAcademicpeer-review

97 Citations (Scopus)


AIMS To study the effect of CYP2D6*4 on antidepressant dose, switching and discontinuation of therapy. METHODS The study consisted of all subjects in the Rotterdam Study, who received a first antidepressant prescription between April 1st 1991 and July 1st 2005 and for whom data on CYP2D6 genotype were available. Binary logistic regression was performed to study the association between CYP2D6*4 and switching to any other antidepressant or discontinuation of therapy within 45 days. The difference in mean antidepressant dose was compared between CYP2D6 genotypes using t-tests and repeated measurements analyses. RESULTS In users of tricyclic antidepressants (TCAs) the risk of switching to another antidepressant was significantly higher in poor metabolizers (PMs:*4/*4) compared with extensive metabolizers (EMs:*1/*1), with an adjusted OR of 5.77 (95% CI 1.59, 21.03; P = 0.01). In SSRI users there was no significant difference (OR 0.91; 95% CI 0.20, 4.15; P = 0.90). Heterozygous patients did not have an increased risk of switching in both TCA and SSRI users. The mean TCA dose was significantly lower in PMs than in EMs at the third and fourth prescription (difference 0.11 DDD, P = 0.03). In SSRI users the difference in mean dose between PMs and EMs was significant at the third prescription (0.17 DDD; P = 0.02). CONCLUSIONS The risk of switching to another antidepressant in TCA users is higher in PMs than in EMs. The maintenance doses of antidepressants were significantly lower in PMs. However, the question whether genotyping prior to the start of antidepressant therapy contributes substantially to the optimization of pharmacotherapy, requires further study.
Original languageUndefined/Unknown
Pages (from-to)558-564
Number of pages7
JournalBritish Journal of Clinical Pharmacology
Issue number4
Publication statusPublished - 2008

Research programs

  • EMC MM-04-39-05
  • EMC NIHES-01-64-03
  • EMC NIHES-03-77-02
  • EMC OR-01-25-01
  • EMC OR-01-34-01

Cite this